What is the appropriate workup and management for thrombocytosis?

Thrombocytosis: Workup and Management

For thrombocytosis (platelet count ≥450 × 10³/μL), confirm with repeat CBC and peripheral smear, then systematically exclude secondary causes before pursuing myeloproliferative neoplasm workup with JAK2, CALR, and MPL mutation testing plus bone marrow biopsy if indicated 1.

Initial Diagnostic Approach

Confirm True Thrombocytosis

• Repeat complete blood count with differential to verify persistent elevation
• Obtain peripheral blood smear to assess platelet morphology and evaluate other cell lines for myeloproliferative features 1
• This step eliminates pseudothrombocytosis from analytical interference 2

Distinguish Secondary vs. Primary Thrombocytosis

Secondary (reactive) thrombocytosis is most common and resolves with treatment of the underlying condition 1. Look for:

• Inflammatory markers: Check C-reactive protein levels 1
• Iron deficiency: Obtain iron studies with ferritin 1
• Clinical context: Infection, malignancy, tissue damage, post-splenectomy, medications, or recent surgery 2, 3

If secondary causes are identified and treated, no further workup is needed unless thrombocytosis persists.

Workup for Primary Thrombocytosis

When thrombocytosis persists without identified secondary cause, pursue essential thrombocythemia (ET) evaluation:

Molecular Testing (Sequential Approach)

1. JAK2 V617F mutation testing first 1
2. If JAK2 negative, test for CALR mutations 1
3. If both negative, test for MPL mutations 1
4. Approximately 80% of ET patients harbor one of these mutations in mutually exclusive fashion 4, 5

Bone Marrow Biopsy

• Required for definitive diagnosis 1
• Shows increased mature-appearing megakaryocytes in loose clusters 5
• Critical to exclude prefibrotic myelofibrosis, which has different prognosis and management 5
• Also excludes polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts 5

Additional Cytogenetic Testing

• Karyotype analysis (abnormal in <10% of cases) 5
• May identify prognostically relevant mutations (TET2, ASXL1, DNMT3A, SF3B1) 5

Risk Stratification for Essential Thrombocythemia

Use a two-variable system based on age and thrombosis history 4:

Risk Categories

• High-risk: Age >60 years OR prior thrombosis history
• Intermediate-risk: Age >60 years with JAK2 mutation but no thrombosis history 5
• Low-risk: Age ≤60 years, JAK2 mutation present, no thrombosis history 5
• Very low-risk: Age ≤60 years, JAK2 wild-type, no thrombosis history 5

Special Considerations

• Extreme thrombocytosis (>1,500 × 10³/μL) is a bleeding risk and warrants cytoreductive therapy 6, 4
• Thrombocytosis >1,000 × 10³/μL increases hemorrhage risk; use aspirin cautiously 4

Management Strategy

All Patients

• Low-dose aspirin once daily for all patients 5
• Twice-daily aspirin for low-risk disease 5
• Aggressively manage cardiovascular risk factors and advise smoking cessation 6, 4

Low-Risk Patients

• Aspirin therapy alone
• No cytoreductive therapy unless platelet count exceeds 1,500 × 10³/μL 6
• Monitor for progression to high-risk category

High-Risk Patients

Cytoreductive therapy is mandatory 6, 4:

First-Line Cytoreductive Therapy

• Hydroxyurea is the first-line agent at any age 6, 1, 5
• In young patients (<40 years), carefully consider hydroxyurea use due to potential leukemogenic risk 6
• Pegylated interferon-α is alternative first-line, particularly for young patients and pregnancy 5

Second-Line Therapy

• Anagrelide is recommended second-line for hydroxyurea intolerance or resistance 6
• Interferon for selected patients (young females, contraindications to anagrelide) 6
• Busulfan for refractory cases 5

Critical caveat: The PT-1 trial demonstrated hydroxyurea plus aspirin reduced thrombotic complications compared to anagrelide plus aspirin 6, making hydroxyurea the superior first choice.

Intermediate-Risk Patients

• Cytoreductive therapy is optional 5
• Consider based on additional risk factors (JAK2 mutation status, extreme thrombocytosis, cardiovascular risk burden)

When to Change Therapy

Indications for Treatment Modification

• Intolerance to hydroxyurea (Table 4 criteria in guidelines) 6
• Progressive myeloproliferation (increasing splenomegaly, uncontrolled symptoms) 6
• Major bleeding complications (withdraw aspirin) 6
• Platelet count rising above 1,500 × 10³/μL despite therapy

Important warning: Patients receiving multiple cytotoxic agents have significantly higher risk of acute myeloid leukemia/myelodysplastic syndromes 6. Prioritize non-leukemogenic drugs (anagrelide, interferon) for second-line therapy.

Monitoring

• No routine bone marrow monitoring for clinical follow-up 6
• Bone marrow biopsy only for suspected transformation to myelofibrosis or acute leukemia 6
• No routine JAK2V617F allele burden monitoring except post-allogeneic transplant or possibly during interferon treatment 4
• Monitor blood counts and symptoms for treatment response 6

Prognosis

No current treatments increase survival or prevent progression to myelofibrosis or leukemia 1. Median survival approximates 18 years overall but exceeds 35 years in younger patients 5. Leukemic transformation rate at 10 years is <1% 5.